Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856384 | 0.99 | ALDH1A1 (0.48) | ALDH1A1PRKCAPRKCDNR1I2FAAH | |
| SCHEMBL6295996 | 0.97 | ALDH1A1 (0.46) | ALDH1A1PRKCAPRKCDNR1I2FAAH | |
| SCHEMBL6296114 | 0.96 | ALDH1A1 (0.48) | ALDH1A1PRKCAPRKCDNR1I2FAAH | |
| SCHEMBL6855748 | 0.96 | PRKCA (0.45) | ALDH1A1PRKCAPRKCDNR1I2FAAH | |
| SCHEMBL6293031 | 0.93 | PRKCA (0.45) | ALDH1A1PRKCAPRKCDNR1I2FAAH | |
| SCHEMBL6856281 | 0.91 | PRKCA (0.43) | ALDH1A1PRKCAPRKCDNR1I2TSHR | |
| SCHEMBL6291923 | 0.88 | PRKCA (0.43) | ALDH1A1PRKCAPRKCDNR1I2TSHR | |
| SCHEMBL6855985 | 0.86 | PRKCA (0.59) | PRKCAPRKCDNR1I2 | |
| SCHEMBL6850439 | 0.85 | ALDH1A1 (0.47) | ALDH1A1PRKCAPRKCDFAAHCNR1 | |
| SCHEMBL6295997 | 0.85 | ALDH1A1 (0.47) | ALDH1A1PRKCAPRKCDFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6830859-B2 | Electrostatic latent images; containing barium salt of sulfoisophthalic acid | RICOH COMPANY, LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-20030077534-A1 | Charge control agent and toner using same | RICOH COMPANY, LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030077534-A1 | Charge control agent and toner using same | BET1, SMARCA5, SMARCA1 | ALDH1A1 4656/4885PRKCA 4466/4885PRKCD 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.